Roth Capital Analysts Raise Earnings Estimates for MBRX

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Stock analysts at Roth Capital raised their Q2 2025 earnings estimates for Moleculin Biotech in a report released on Wednesday, May 14th. Roth Capital analyst J. Aschoff now forecasts that the company will earn ($0.42) per share for the quarter, up from their prior estimate of ($0.46). The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. Roth Capital also issued estimates for Moleculin Biotech’s Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.77) EPS, FY2026 earnings at ($1.50) EPS, FY2027 earnings at ($1.44) EPS, FY2028 earnings at ($1.38) EPS and FY2029 earnings at $1.18 EPS.

Several other research analysts also recently commented on MBRX. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Moleculin Biotech in a research note on Monday, March 24th. Maxim Group raised shares of Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a report on Tuesday, March 25th. Finally, StockNews.com raised shares of Moleculin Biotech to a “sell” rating in a research note on Wednesday, March 26th.

Moleculin Biotech Stock Performance

NASDAQ MBRX opened at $0.91 on Friday. The stock’s 50 day simple moving average is $0.99 and its 200-day simple moving average is $1.59. Moleculin Biotech has a 1-year low of $0.40 and a 1-year high of $5.18.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.02. During the same quarter in the previous year, the business earned ($2.02) earnings per share.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC increased its position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) by 293.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,250,000 shares of the company’s stock after acquiring an additional 932,414 shares during the quarter. Armistice Capital LLC owned approximately 8.93% of Moleculin Biotech worth $1,217,000 as of its most recent filing with the Securities and Exchange Commission. 15.52% of the stock is owned by institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.